125 related articles for article (PubMed ID: 37828983)
1. Erratum: IGF2BP family of RNA-binding proteins regulate innate and adaptive immune responses in cancer cells and tumor microenvironment.
Frontiers Production Office
Front Immunol; 2023; 14():1297519. PubMed ID: 37828983
[TBL] [Abstract][Full Text] [Related]
2. IGF2BP family of RNA-binding proteins regulate innate and adaptive immune responses in cancer cells and tumor microenvironment.
Elcheva IA; Gowda CP; Bogush D; Gornostaeva S; Fakhardo A; Sheth N; Kokolus KM; Sharma A; Dovat S; Uzun Y; Schell TD; Spiegelman VS
Front Immunol; 2023; 14():1224516. PubMed ID: 37503349
[TBL] [Abstract][Full Text] [Related]
3. IGF2BPs as novel m
Duan M; Liu H; Xu S; Yang Z; Zhang F; Wang G; Wang Y; Zhao S; Jiang X
Genes Dis; 2024 Mar; 11(2):890-920. PubMed ID: 37692485
[TBL] [Abstract][Full Text] [Related]
4. Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade.
Benci JL; Johnson LR; Choa R; Xu Y; Qiu J; Zhou Z; Xu B; Ye D; Nathanson KL; June CH; Wherry EJ; Zhang NR; Ishwaran H; Hellmann MD; Wolchok JD; Kambayashi T; Minn AJ
Cell; 2019 Aug; 178(4):933-948.e14. PubMed ID: 31398344
[TBL] [Abstract][Full Text] [Related]
5. Erratum: New insights into the role of macrophages in cancer immunotherapy.
Frontiers Production Office
Front Immunol; 2024; 15():1427337. PubMed ID: 38817610
[TBL] [Abstract][Full Text] [Related]
6. Erratum: Development of immunotherapy strategies targeting tumor microenvironment is fiercely ongoing.
Frontiers Production Office
Front Immunol; 2022; 13():1004587. PubMed ID: 36032087
[TBL] [Abstract][Full Text] [Related]
7. Corrigendum: Innate Immune Cells in the Esophageal Tumor Microenvironment.
Cui K; Hu S; Mei X; Cheng M
Front Immunol; 2021; 12():708705. PubMed ID: 34122459
[TBL] [Abstract][Full Text] [Related]
8. The IGF2BP family of RNA binding proteins links epitranscriptomics to cancer.
Ramesh-Kumar D; Guil S
Semin Cancer Biol; 2022 Nov; 86(Pt 3):18-31. PubMed ID: 35643219
[TBL] [Abstract][Full Text] [Related]
9. Erratum: Mechanisms of extracellular vesicle-mediated immune evasion in melanoma.
Frontiers Production Office
Front Immunol; 2023; 14():1178158. PubMed ID: 36993951
[TBL] [Abstract][Full Text] [Related]
10. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors.
Yi M; Niu M; Wu Y; Ge H; Jiao D; Zhu S; Zhang J; Yan Y; Zhou P; Chu Q; Wu K
J Hematol Oncol; 2022 Oct; 15(1):142. PubMed ID: 36209176
[TBL] [Abstract][Full Text] [Related]
11. m
Wang L; Hui H; Agrawal K; Kang Y; Li N; Tang R; Yuan J; Rana TM
EMBO J; 2020 Oct; 39(20):e104514. PubMed ID: 32964498
[TBL] [Abstract][Full Text] [Related]
12. Erratum: Immunotherapy for Glioblastoma: Current Progress and Challenges.
Frontiers Production Office
Front Immunol; 2021; 12():782687. PubMed ID: 34691087
[TBL] [Abstract][Full Text] [Related]
13. Erratum: Immune Tumor Microenvironment in Breast Cancer and the Participation of Estrogen and Its Receptors in Cancer Physiopathology.
Frontiers Production Office
Front Immunol; 2019; 10():1868. PubMed ID: 31447856
[TBL] [Abstract][Full Text] [Related]
14. Erratum: Rapid generation of TCR and CD8αβ transgenic virus specific T cells for immunotherapy of leukemia.
Frontiers Production Office
Front Immunol; 2023; 14():1185223. PubMed ID: 37033987
[TBL] [Abstract][Full Text] [Related]
15. Corrigendum: Characterizing the Role of Monocytes in T Cell Cancer Immunotherapy Using a 3D Microfluidic Model.
Lee SWL; Adriani G; Ceccarello E; Pavesi A; Tan AT; Bertoletti A; Kamm RD; Wong SC
Front Immunol; 2018; 9():1719. PubMed ID: 30083166
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
18. Novel growth and death related interferon-stimulated genes (ISGs) in melanoma: greater potency of IFN-beta compared with IFN-alpha2.
Leaman DW; Chawla-Sarkar M; Jacobs B; Vyas K; Sun Y; Ozdemir A; Yi T; Williams BR; Borden EC
J Interferon Cytokine Res; 2003 Dec; 23(12):745-56. PubMed ID: 14769151
[TBL] [Abstract][Full Text] [Related]
19. Erratum: Overcoming immune resistance with radiation therapy in prostate cancer.
Frontiers Production Office
Front Immunol; 2023; 14():1185185. PubMed ID: 37033975
[TBL] [Abstract][Full Text] [Related]
20. Systematic Analysis of the Expression Profile and Prognostic Significance of the IGF2BP Family in Lung Adenocarcinoma.
Zhou Z; Zhu T; Chen S; Qin S; Huang Y; Liu D
Curr Cancer Drug Targets; 2022; 22(4):340-350. PubMed ID: 35232349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
